{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:07:27Z","timestamp":1781863647620,"version":"3.54.5"},"reference-count":97,"publisher":"Oxford University Press (OUP)","issue":"1111","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000288","name":"Royal Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011264","name":"FP7 People: Marie-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000288","name":"Royal Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011264","name":"FP7 People: Marie-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011264","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Duchenne muscular dystrophy (DMD) is a progressive wasting disease of skeletal and cardiac muscles, representing one of the most common recessive fatal inherited genetic diseases with 1:3500\u20131:5000 in yearly incidence. It is caused by mutations in the DMD gene that encodes the membrane-associated dystrophin protein. Over the years, many have been the approaches to management of DMD, but despite all efforts, no effective treatment has yet been discovered. Hope for the development of potential therapeutics has followed the recent advances in genome editing and gene therapy. This review gives an overview to DMD and summarises current lines of evidence with regard to treatment and disease management alongside the appropriate considerations.<\/jats:p>","DOI":"10.1136\/postgradmedj-2017-135377","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T17:45:23Z","timestamp":1517420723000},"page":"296-304","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Duchenne muscular dystrophy: genome editing gives new hope for treatment"],"prefix":"10.1093","volume":"94","author":[{"given":"Vassili","family":"Crispi","sequence":"first","affiliation":[{"name":"Molecular Physiology Laboratory, Centre for Atherothrombotic and Metabolic Disease, Hull York Medical School, University of Hull , Hull , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Matsakas","sequence":"additional","affiliation":[{"name":"Molecular Physiology Laboratory, Centre for Atherothrombotic and Metabolic Disease, Hull York Medical School, University of Hull , Hull , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1590\/0004-282x20170086","article-title":"Duchenne muscular dystrophy: classical and new therapeutic purposes and future perspectives","volume":"75","author":"Souza","year":"2017","journal-title":"Arq Neuropsiquiatr"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5435\/00124635-200203000-00009","article-title":"Duchenne muscular dystrophy","volume":"10","author":"Sussman","year":"2002","journal-title":"J Am Acad Orthop Surg"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10974-015-9438-9","article-title":"The role of oxidative stress in skeletal muscle injury and regeneration: focus on antioxidant enzymes","volume":"36","author":"Kozakowska","year":"2015","journal-title":"J Muscle Res Cell Motil"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11832-015-0683-7","article-title":"Simultaneous progression patterns of scoliosis, pelvic obliquity, and hip subluxation\/dislocation in non-ambulatory neuromuscular patients: an approach to deformity documentation","volume":"9","author":"Patel","year":"2015","journal-title":"J Child Orthop"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0034-1398689","article-title":"Cardiomyopathy in duchenne muscular dystrophy: Current value of clinical, electrophysiological and imaging findings in children and teenagers","volume":"227","author":"Dittrich","year":"2015","journal-title":"Klin Padiatr"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/0471142905.hg0925s83","article-title":"Molecular diagnosis of Duchenne muscular dystrophy","volume":"83","author":"Nallamilli","year":"2014","journal-title":"Current protocols in human genetics"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","article-title":"The pathogenesis and therapy of muscular dystrophies","volume":"16","author":"Guiraud","year":"2015","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"Pt 8","key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1242\/jcs.02857","article-title":"Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex","volume":"119","author":"Judge","year":"2006","journal-title":"J Cell Sci"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0002-9440(10)63523-7","article-title":"Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins","volume":"163","author":"Bonuccelli","year":"2003","journal-title":"Am J Pathol"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1161\/01.RES.0000126574.61061.25","article-title":"The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma","volume":"94","author":"Lapidos","year":"2004","journal-title":"Circ Res"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00007.2015","article-title":"Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive Oxygen Species, and Nitric Oxide in the development of muscular dystrophy","volume":"96","author":"Allen","year":"2016","journal-title":"Physiol Rev"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/ng0295-184","article-title":"The human dystrophin gene requires 16 hours to be transcribed and is cotranscriptionally spliced","volume":"9","author":"Tennyson","year":"1995","journal-title":"Nat Genet"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00439-016-1725-z","article-title":"Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy","volume":"135","author":"Robinson-Hamm","year":"2016","journal-title":"Hum Genet"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.pmr.2012.06.011","article-title":"Clinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseases","volume":"23","author":"McDonald","year":"2012","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.nmd.2017.06.555","article-title":"Diagnosis of Duchenne muscular dystrophy in Italy in the last decade: Critical issues and areas for improvements","volume":"27","author":"Haliloglu","year":"2017","journal-title":"Neuromuscular Disorders"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nmd.2017.02.006","article-title":"Diagnosis of duchenne muscular dystrophy in Italy in the last decade: Critical issues and areas for improvements","volume":"27","author":"D\u2019Amico","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.4155\/cli.11.113","article-title":"Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings","volume":"1","author":"Bushby","year":"2011","journal-title":"Clin Investig"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mus.23902","article-title":"The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/humu.21426","article-title":"Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene","volume":"32","author":"Flanigan","year":"2011","journal-title":"Hum Mutat"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/BF00858725","article-title":"The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history","volume":"240","author":"Bushby","year":"1993","journal-title":"J Neurol"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1086\/374176","article-title":"Rapid direct sequence analysis of the dystrophin gene","volume":"72","author":"Flanigan","year":"2003","journal-title":"Am J Hum Genet"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/(SICI)1097-0223(199910)19:10<921::AID-PD660>3.0.CO;2-A","article-title":"Fetal muscle biopsy as a diagnostic tool in Duchenne muscular dystrophy","volume":"19","author":"Nevo","year":"1999","journal-title":"Prenat Diagn"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.nmd.2017.06.557","article-title":"A comparative study of care practices for young boys with Duchenne muscular dystrophy between Japan and European countries: Implications of early diagnosis","volume":"27","author":"Takeuchi","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","article-title":"Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study","volume":"13","author":"Voit","year":"2014","journal-title":"Lancet Neurol"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/WCO.0000000000000235","article-title":"An update on RNA-targeting therapies for neuromuscular disorders","volume":"28","author":"Jirka","year":"2015","journal-title":"Curr Opin Neurol"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/hrt.2007.121558","article-title":"Cardiopulmonary exercise testing and its application","volume":"83","author":"Albouaini","year":"2007","journal-title":"Postgrad Med J"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/PEP.0000000000000160","article-title":"Commentary on \u201ccardiopulmonary exercise testing in children and adolescents with dystrophinopathies: A pilot study\u201d","volume":"27","author":"Case","year":"2015","journal-title":"Pediatr Phys Ther"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/PEP.0000000000000159","article-title":"Cardiopulmonary exercise testing in children and adolescents with dystrophinopathies: a pilot study","volume":"27","author":"Bartels","year":"2015","journal-title":"Pediatr Phys Ther"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0883073810371004","article-title":"Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management","volume":"25","author":"Moxley","year":"2010","journal-title":"J Child Neurol"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.1023","article-title":"Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations","volume":"49","author":"Wagner","year":"2001","journal-title":"Ann Neurol"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/jb\/mvg203","article-title":"Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice","volume":"134","author":"Arakawa","year":"2003","journal-title":"J Biochem"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/jnnp-2012-303902","article-title":"Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy","volume":"84","author":"Ricotti","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/cr.2016.28","article-title":"Duchenne muscular dystrophy: CRISPR\/Cas9 treatment","volume":"26","author":"Mendell","year":"2016","journal-title":"Cell Res"},{"key":"2023041307435685700_","article-title":"Energy expenditure, body composition, and prevalence of metabolic disorders in patients with Duchenne muscular dystrophy","author":"Saure","year":"2017","journal-title":"Diabetes Metab Syndr"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1517\/21678707.2015.1088780","article-title":"Gene Therapy for Duchenne muscular dystrophy","volume":"3","author":"Ramos","year":"2015","journal-title":"Expert Opin Orphan Drugs"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1096\/fj.13-228296","article-title":"Muscle ERR\u03b3 mitigates Duchenne muscular dystrophy via metabolic and angiogenic reprogramming","volume":"27","author":"Matsakas","year":"2013","journal-title":"Faseb J"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/stem.1402","article-title":"A new immuno-, dystrophin-deficient model, the NSG-mdx(4Cv) mouse, provides evidence for functional improvement following allogeneic satellite cell transplantation","volume":"31","author":"Arpke","year":"2013","journal-title":"Stem Cells"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1369\/jhc.6R6995.2006","article-title":"The skeletal muscle satellite cell: the stem cell that came in from the cold","volume":"54","author":"Zammit","year":"2006","journal-title":"J Histochem Cytochem"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.cell.2005.05.010","article-title":"Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche","volume":"122","author":"Collins","year":"2005","journal-title":"Cell"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1242\/dmm.018424","article-title":"Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy","volume":"8","author":"McGreevy","year":"2015","journal-title":"Dis Model Mech"},{"key":"2023041307435685700_","first-page":"S10-001","article-title":"Engraftment of ES-Derived Myogenic Progenitors in a Severe Mouse Model of Muscular Dystrophy","volume":"10","author":"Filareto","year":"2012","journal-title":"J Stem Cell Res Ther"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.trsl.2013.11.006","article-title":"Stem cells for skeletal muscle regeneration: therapeutic potential and roadblocks","volume":"163","author":"Rinaldi","year":"2014","journal-title":"Transl Res"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0022-510X(93)90224-M","article-title":"Long-term persistence and migration of myogenic cells injected into pre-irradiated muscles of mdx mice","volume":"115","author":"Morgan","year":"1993","journal-title":"J Neurol Sci"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ncb1542","article-title":"Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells","volume":"9","author":"Dellavalle","year":"2007","journal-title":"Nat Cell Biol"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","article-title":"Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients","volume":"13","author":"Schwank","year":"2013","journal-title":"Cell Stem Cell"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2008.05.049","article-title":"Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles","volume":"134","author":"Cerletti","year":"2008","journal-title":"Cell"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1126\/science.1114758","article-title":"Direct isolation of satellite cells for skeletal muscle regeneration","volume":"309","author":"Montarras","year":"2005","journal-title":"Science"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/WCO.0000000000000241","article-title":"Viral vector-mediated gene therapies","volume":"28","author":"Hollinger","year":"2015","journal-title":"Curr Opin Neurol"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.12688\/f1000research.8735.1","article-title":"Advances in gene therapy for muscular dystrophies","volume":"5","author":"Abdul-Razak","year":"2016","journal-title":"F1000Res"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1089\/hum.2013.164","article-title":"Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice","volume":"25","author":"Koo","year":"2014","journal-title":"Hum Gene Ther"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1089\/hum.2013.210","article-title":"Full-length dystrophin reconstitution with adeno-associated viral vectors","volume":"25","author":"Lostal","year":"2014","journal-title":"Hum Gene Ther"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nbt1073","article-title":"Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart","volume":"23","author":"Wang","year":"2005","journal-title":"Nat Biotechnol"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"13714","DOI":"10.1073\/pnas.240335297","article-title":"Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model","volume":"97","author":"Wang","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/mt.2008.28","article-title":"Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice","volume":"16","author":"Gregorevic","year":"2008","journal-title":"Mol Ther"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1089\/hum.2008.058","article-title":"Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice","volume":"19","author":"Bostick","year":"2008","journal-title":"Hum Gene Ther"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/jor.20781","article-title":"Systemic human minidystrophin gene transfer improves functions and life span of dystrophin and dystrophin\/utrophin-deficient mice","volume":"27","author":"Wang","year":"2009","journal-title":"J Orthop Res"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/mt.2012.283","article-title":"Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy","volume":"21","author":"Shin","year":"2013","journal-title":"Mol Ther"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"16105","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"Le Guiner","year":"2017","journal-title":"Nat Commun"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jgm.1602","article-title":"Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog","volume":"13","author":"Koo","year":"2011","journal-title":"J Gene Med"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039233","article-title":"Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer","volume":"7","author":"Grose","year":"2012","journal-title":"PLoS One"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCRESAHA.117.310996","article-title":"In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice","volume":"121","author":"El Refaey","year":"2017","journal-title":"Circ Res"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/mt.2014.200","article-title":"A phase 1\/2a follistatin gene therapy trial for becker muscular dystrophy","volume":"23","author":"Mendell","year":"2015","journal-title":"Mol Ther"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/mt.2016.10","article-title":"Genome-editing technologies for gene and cell therapy","volume":"24","author":"Maeder","year":"2016","journal-title":"Mol Ther"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.molmed.2016.01.007","article-title":"Exon snipping in duchenne muscular dystrophy","volume":"22","author":"Kemaladewi","year":"2016","journal-title":"Trends Mol Med"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14712598.2017.1271872","article-title":"Exon skipping: a first in class strategy for Duchenne muscular dystrophy","volume":"17","author":"Niks","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"2023041307435685700_","first-page":"31","article-title":"Duchenne muscular dystrophy gene therapy: lost in translation?","volume":"2011","author":"Duan","year":"2011","journal-title":"Res Rep Biol"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/mt.2010.72","article-title":"Preclinical PK and PD studies on 2\u2019-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model","volume":"18","author":"Heemskerk","year":"2010","journal-title":"Mol Ther"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omtn.2017.06.013","article-title":"Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model","volume":"8","author":"Relizani","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omtn.2017.02.007","article-title":"CRISPR\/Cas9-mediated genome editing corrects dystrophin mutation in skeletal muscle stem cells in a mouse model of muscle dystrophy","volume":"7","author":"Zhu","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/CIRCULATIONAHA.116.024007","article-title":"CRISPR (clustered regularly interspaced palindromic repeat)\/cas9 system: a revolutionary disease-modifying technology","volume":"134","author":"Munshi","year":"2016","journal-title":"Circulation"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nbt.2842","article-title":"CRISPR-Cas systems for editing, regulating and targeting genomes","volume":"32","author":"Sander","year":"2014","journal-title":"Nat Biotechnol"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1093\/hmg\/ddv420","article-title":"Progress and prospects of gene therapy clinical trials for the muscular dystrophies","volume":"25","author":"Bengtsson","year":"2016","journal-title":"Hum Mol Genet"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.omtn.2016.11.004","article-title":"increased expression of laminin subunit alpha 1 Chain by dCas9-VP160","volume":"6","author":"Perrin","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.1038\/ncomms7244","article-title":"Multiplex CRISPR\/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy","volume":"6","author":"Ousterout","year":"2015","journal-title":"Nat Commun"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1093\/hmg\/ddv120","article-title":"Functional disruption of the dystrophin gene in rhesus monkey using CRISPR\/Cas9","volume":"24","author":"Chen","year":"2015","journal-title":"Hum Mol Genet"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3233\/JND-170218","article-title":"creation of a novel humanized dystrophic mouse model of duchenne muscular dystrophy and application of a CRISPR\/Cas9 gene editing therapy","volume":"4","author":"Young","year":"2017","journal-title":"J Neuromuscul Dis"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.1254445","article-title":"Prevention of muscular dystrophy in mice by CRISPR\/Cas9-mediated editing of germline DNA","volume":"345","author":"Long","year":"2014","journal-title":"Science"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"37051","DOI":"10.1038\/srep37051","article-title":"Adenoviral vectors encoding CRISPR\/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells","volume":"6","author":"Maggio","year":"2016","journal-title":"Sci Rep"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23305","article-title":"Correction of a pathogenic gene mutation in human embryos","volume":"548","author":"Ma","year":"2017","journal-title":"Nature"},{"key":"2023041307435685700_","article-title":"ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world","author":"U.S National Library of Medicine","year":"2017"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/acn3.440","article-title":"Respiratory magnetic resonance imaging biomarkers in Duchenne muscular dystrophy","volume":"4","author":"Mankodi","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13023-017-0590-8","article-title":"Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial","volume":"12","author":"Raman","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1212\/WNL.0000000000004570","article-title":"A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy","volume":"89","author":"Victor","year":"2017","journal-title":"Neurology"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3233\/JND-170245","article-title":"Efficacy of Idebenone to Preserve Respiratory Function above Clinically Meaningful Thresholds for Forced Vital Capacity (FVC) in Patients with Duchenne Muscular Dystrophy","volume":"4","author":"Mayer","year":"2017","journal-title":"J Neuromuscul Dis"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with Duchenne muscular dystrophy","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/mt.2011.237","article-title":"Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector","volume":"20","author":"Bowles","year":"2012","journal-title":"Mol Ther"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161955","article-title":"Long-term efficacy, safety, and pharmacokinetics of drisapersen in duchenne muscular dystrophy: results from an open-label extension study","volume":"11","author":"Goemans","year":"2016","journal-title":"PLoS One"},{"key":"2023041307435685700_","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann Neurol"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/94\/1111\/296\/49838897\/postgradmedj-94-296.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/94\/1111\/296\/49838897\/postgradmedj-94-296.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T21:43:14Z","timestamp":1719783794000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/94\/1111\/296\/6959164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":97,"journal-issue":{"issue":"1111","published-online":{"date-parts":[[2018,1,31]]},"published-print":{"date-parts":[[2018,5,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2017-135377","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,5]]},"published":{"date-parts":[[2018,1,31]]}}}